GR-125743|CAS 148547-33-5|DC Chemicals

Cas No.:	148547-33-5
Chemical Name:	GR 125743
SMILES:	O=C(C1=CC=C(C(C)=C1)C2=CC=NC=C2)NC3=CC=C(C(N4CCN(CC4)C)=C3)OC
Formula:	C₂₅H₂₈N₄O₂
M.Wt:	416.52
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1: Riahi G, Morissette M, Samadi P, Parent M, Di Paolo T. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochem Pharmacol. 2013 Oct 1;86(7):970-8. doi: 10.1016/j.bcp.2013.08.005. Epub 2013 Aug 14. PMID: 23954709. 2: du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2014 Jan;24(1):160-71. doi: 10.1016/j.euroneuro.2013.07.001. Epub 2013 Aug 2. PMID: 23916504. 3: Storvik M, Häkkinen M, Tupala E, Tiihonen J. Whole-hemisphere autoradiography of 5-HT₁B receptor densities in postmortem alcoholic brains. Psychiatry Res. 2012 Jun 30;202(3):264-70. doi: 10.1016/j.pscychresns.2011.11.001. Epub 2012 Jul 16. PMID: 22804971. 4: Kaspersen H, Agmo A. Paroxetine-induced reduction of sexual incentive motivation in female rats is not modified by 5-HT1B or 5-HT2C antagonists. Psychopharmacology (Berl). 2012 Mar;220(2):269-80. doi: 10.1007/s00213-011-2475-1. Epub 2011 Sep 10. PMID: 21909633. 5: Smith GT, Combs N. Serotonergic activation of 5HT1A and 5HT2 receptors modulates sexually dimorphic communication signals in the weakly electric fish Apteronotus leptorhynchus. Horm Behav. 2008 Jun;54(1):69-82. doi: 10.1016/j.yhbeh.2008.01.009. Epub 2008 Feb 9. PMID: 18336816. 6: Hanff LM, Gupta S, MaassenVanDenBrink A, Steegers EA, Saxena PR, Vulto AG, Visser W. The effect of maternal ketanserin treatment on foetal 5-HT receptor function in umbilical cord artery of pre-eclamptic patients. Neonatology. 2007;92(4):240-7. doi: 10.1159/000103742. Epub 2007 Jun 8. PMID: 17556842. 7: Ahlgren C, Eriksson A, Tellefors P, Ross SB, Stenfors C, Malmberg A. In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine(1B) autoreceptor antagonist. Eur J Pharmacol. 2004 Sep 19;499(1-2):67-75. doi: 10.1016/j.ejphar.2004.07.067. PMID: 15363952. 8: Przegaliński E, Czepiel K, Nowak E, Dlaboga D, Filip M. Withdrawal from chronic cocaine up-regulates 5-HT1B receptors in the rat brain. Neurosci Lett. 2003 Nov 20;351(3):169-72. doi: 10.1016/j.neulet.2003.08.007. PMID: 14623133. 9: Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramírez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology. 2004 Feb;29(2):410-6. doi: 10.1038/sj.npp.1300330. PMID: 14571255. 10: Millan MJ, Newman-Tancredi A, Lochon S, Touzard M, Aubry S, Audinot V. Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization. Pharmacol Biochem Behav. 2002 Apr;71(4):589-98. doi: 10.1016/s0091-3057(01)00716-x. PMID: 11888550. 11: Varnäs K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res. 2001 Oct 5;915(1):47-57. doi: 10.1016/s0006-8993(01)02823-2. PMID: 11578619. 12: Bhalla P, Sharma HS, Ma X, Wurch T, Pauwels PJ, Saxena PR. Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptor. Br J Pharmacol. 2001 Jul;133(6):891-901. doi: 10.1038/sj.bjp.0704150. PMID: 11454663; PMCID: PMC1572856. 13: Grånäs C, Nordquist J, Mohell N, Larhammar D. Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist low-affinity conformation and reduces the intrinsic activity of 5-HT. Eur J Pharmacol. 2001 Jun 8;421(2):69-76. doi: 10.1016/s0014-2999(01)01027-5. PMID: 11399261. 14: Audinot V, Newman-Tancredi A, Millan MJ. Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms. Neuropharmacology. 2001;40(1):57-64. doi: 10.1016/s0028-3908(00)00104-0. PMID: 11077071. 15: Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR. Molecular cloning, sequence analysis and pharmacological properties of the porcine 5-HT(1D) receptor. Br J Pharmacol. 2000 Nov;131(5):949-57. doi: 10.1038/sj.bjp.0703645. PMID: 11053216; PMCID: PMC1572407. 16: van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73. doi: 10.1016/s0014-2999(00)00712-3. PMID: 11050304. 17: Wurch T, Palmier C, Pauwels PJ. Induction of a high-affinity ketanserin binding site at the 5-Hydroxytryptamine(1B) receptor by modification of its carboxy-terminal intracellular portion. Biochem Pharmacol. 2000 May 1;59(9):1117-21. doi: 10.1016/s0006-2952(99)00416-5. PMID: 10704941. 18: Grånäs C, Larhammar D. Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. Eur J Pharmacol. 1999 Sep 10;380(2-3):171-81. doi: 10.1016/s0014-2999(99)00520-8. PMID: 10513577. 19: Xie Z, Lee SP, O'Dowd BF, George SR. Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7. doi: 10.1016/s0014-5793(99)00918-7. PMID: 10452531. 20: Bonaventure P, Umans L, Bakker MH, Cras P, Langlois X, Luyten WH, Megens AA, Serneels L, Van Leuven F, Leysen JE. Humanization of mouse 5-hydroxytryptamine1B receptor gene by homologous recombination: in vitro and in vivo characterization. Mol Pharmacol. 1999 Jul;56(1):54-67. doi: 10.1124/mol.56.1.54. PMID: 10385684.

Cat. No.	Product name	Field of application
DC60859	MT-125(MT 125)	MT125 is a brain-penetrant small-molecule inhibitor selectively targeting non-muscle myosin IIA/B (NMIIA/B) with >20-fold specificity over cardiac myosin. It demonstrates potent anti-glioblastoma activity by: (1) blocking tumor invasion and cytokinesis (inducing polyploidy), (2) disrupting mitochondrial dynamics to elevate ROS and trigger ferroptosis, and (3) sensitizing tumors to radiotherapy/kinase inhibitors via ROS-driven PDGFR/mTOR pathway activation. Subcutaneous administration achieves brain concentrations twice plasma levels (t_1/2~10.5 hr) with no toxicity observed at 15× the therapeutic dose in rats. MT-125 monotherapy extends survival in GBM models, while combinations with PDGFR/PI3K inhibitors induce long-term remission (>40% mice). Its first-in-class mechanism, safety profile, and CNS bioavailability support clinical development for glioblastoma.
DC60781	TRPC6 activator compound 2	TRPC6 activator compound 2 is selective activator of TRPC6 that does not potentiate TRPC3 and mTRPC7. Comp2 is able to cross BBB.
DC66546	R-Sirpiglenastat	R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DC60597	AZD0780	AZD0780 is the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia.
DC90056	PLX-5622 HCl form (water solubility form)	PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development.
DC65830	1-M-PES(1-Methoxy-5-methylphenazinium ethyl sulfate)	1-m-PES is an electron mediator which has higher stability of solutions than 1-Methoxy PMS. The stability in neutral to alkali conditions has been extremely improved with 1-Methoxy PES. 1-M-PES is a stable small-molecular compound and it has an equal or higher thermal stability than diaphorase. The 1-Methoxy PES solution can be stored long term.
DC65821	Upadacitinib hemihydrate	Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.
DC65697	HDAC6 inhibitor 4510	A novel and seletive HDAC6 inhibitor.
DC65676	Fenretinide Glucuronide Monosodium Salt	Fenretinide Glucuronide Monosodium Salt, is the metabolite of Fenretinide (F250000), which is a synthetic retinoid deriverative, substances related to vitamin A. They are also shown to be used for the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, and psoriasis.
DC89083	Pacritinib citrate	Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2).